This Kedbumin market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Growth during the historic period can be attributed to the increasing prevalence of liver and renal diseases, a rising incidence of burns and trauma, growing awareness of the benefits of albumin therapies, enhanced regulatory approvals for albumin-based products, and the increasing use of albumin in surgeries and post-operative care.
Growth during the forecast period is expected to be driven by a rising aging population with associated chronic diseases, increasing global healthcare expenditure, growing demand for effective critical care solutions, a heightened focus on patient-centric treatment options, and government support for plasma collection and albumin therapies. Key trends anticipated include a shift toward personalized medicine and individualized treatments, growth in parenteral nutrition solutions utilizing albumin, increased adoption of albumin-based treatments in low-income regions, expansion of non-hospital settings offering albumin therapies, and the adoption of combination therapies involving albumin.
The increasing prevalence of chronic diseases is expected to drive the growth of the kedbumin market in the future. Chronic diseases are conditions that persist for three months or longer and can worsen over time. Kedbumin helps manage complications such as ascites and spontaneous bacterial peritonitis by improving circulatory function and reducing fluid buildup. For example, in January 2023, The National Center for Biotechnology Information, part of the US-based National Library of Medicine, reported that the number of Americans aged 50 and older with at least one chronic condition is projected to rise by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Thus, the growing prevalence of chronic diseases is a key factor driving the growth of the kedbumin market.
The expanding aging population is expected to further fuel the growth of the kedbumin market. This demographic, consisting of individuals aged 65 and older, is growing due to increased life expectancy and lower birth rates. Advances in healthcare, medical technology, and improved living conditions have contributed to this trend. Kedbumin, a plasma-derived albumin solution, assists the aging population by managing conditions such as hypovolemia, hypoalbuminemia, and associated complications, leading to improved health and recovery outcomes. For instance, in January 2024, statistics from the Population Reference Bureau (PRB), a US-based nonprofit organization, projected that the number of Americans aged 65 and older will grow from 58 million in 2022 to 82 million in 2050, a 47% increase. Their proportion of the total population will rise from 17% to 23%. As a result, the growing aging population is a driving force for the kedbumin market.
In September 2022, the UK-based private equity firm Permira and the Marcucci family made a significant investment in Kedrion Biopharma and Bio Products Laboratory (BPL), marking an important consolidation in the biopharmaceutical sector focused on blood plasma-derived products. This partnership is seen as a major development for both companies, allowing them to better meet the needs of patients globally while capitalizing on the increasing demand for plasma-derived therapies. Kedrion Biopharma, based in Italy, specializes in producing human blood plasma-derived products, while Bio Products Laboratory (BPL) is a UK-based pharmaceutical company.
The company operating in the kedbumin market is Kedrion SpA.
North America was the largest region in the kedbumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kedbumin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kedbumin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Kedbumin is a therapeutic product designed for the management and treatment of conditions related to protein deficiency, commonly used in medical settings to support patients with hypoalbuminemia and related disorders. Kedbumin is a clear, slightly viscous solution that may have an amber, yellow, or green tint. It is stabilized with 0.08 mmol of sodium caprylate and 0.08 mmol of sodium acetyltryptophan per gram of albumin.
The primary indications for kedbumin include the treatment of hypoalbuminemia, fluid resuscitation, management of liver diseases, treatment of burns and trauma, and other conditions. Hypoalbuminemia is a condition characterized by low levels of albumin in the blood, which can lead to various health complications. Kedbumin is available in injectable formulations and lyophilized powders for reconstitution. Its target patient demographics encompass pediatric, adult, and geriatric patients. Distribution channels include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Key end-users are hospitals, specialty clinics, home healthcare providers, pharmaceutical and biotechnology companies, and research institutions.
The kedbumin market research report is one of a series of new reports that provides kedbumin market statistics, including kedbumin industry global market size, regional shares, competitors with a kedbumin market share, detailed kedbumin market segments, market trends and opportunities, and any further data you may need to thrive in the kedbumin industry. This kedbumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The kedbumin market consists of sales of kedbumin products for medical and therapeutic use. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Growth during the historic period can be attributed to the increasing prevalence of liver and renal diseases, a rising incidence of burns and trauma, growing awareness of the benefits of albumin therapies, enhanced regulatory approvals for albumin-based products, and the increasing use of albumin in surgeries and post-operative care.
Growth during the forecast period is expected to be driven by a rising aging population with associated chronic diseases, increasing global healthcare expenditure, growing demand for effective critical care solutions, a heightened focus on patient-centric treatment options, and government support for plasma collection and albumin therapies. Key trends anticipated include a shift toward personalized medicine and individualized treatments, growth in parenteral nutrition solutions utilizing albumin, increased adoption of albumin-based treatments in low-income regions, expansion of non-hospital settings offering albumin therapies, and the adoption of combination therapies involving albumin.
The increasing prevalence of chronic diseases is expected to drive the growth of the kedbumin market in the future. Chronic diseases are conditions that persist for three months or longer and can worsen over time. Kedbumin helps manage complications such as ascites and spontaneous bacterial peritonitis by improving circulatory function and reducing fluid buildup. For example, in January 2023, The National Center for Biotechnology Information, part of the US-based National Library of Medicine, reported that the number of Americans aged 50 and older with at least one chronic condition is projected to rise by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Thus, the growing prevalence of chronic diseases is a key factor driving the growth of the kedbumin market.
The expanding aging population is expected to further fuel the growth of the kedbumin market. This demographic, consisting of individuals aged 65 and older, is growing due to increased life expectancy and lower birth rates. Advances in healthcare, medical technology, and improved living conditions have contributed to this trend. Kedbumin, a plasma-derived albumin solution, assists the aging population by managing conditions such as hypovolemia, hypoalbuminemia, and associated complications, leading to improved health and recovery outcomes. For instance, in January 2024, statistics from the Population Reference Bureau (PRB), a US-based nonprofit organization, projected that the number of Americans aged 65 and older will grow from 58 million in 2022 to 82 million in 2050, a 47% increase. Their proportion of the total population will rise from 17% to 23%. As a result, the growing aging population is a driving force for the kedbumin market.
In September 2022, the UK-based private equity firm Permira and the Marcucci family made a significant investment in Kedrion Biopharma and Bio Products Laboratory (BPL), marking an important consolidation in the biopharmaceutical sector focused on blood plasma-derived products. This partnership is seen as a major development for both companies, allowing them to better meet the needs of patients globally while capitalizing on the increasing demand for plasma-derived therapies. Kedrion Biopharma, based in Italy, specializes in producing human blood plasma-derived products, while Bio Products Laboratory (BPL) is a UK-based pharmaceutical company.
The company operating in the kedbumin market is Kedrion SpA.
North America was the largest region in the kedbumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kedbumin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kedbumin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Kedbumin is a therapeutic product designed for the management and treatment of conditions related to protein deficiency, commonly used in medical settings to support patients with hypoalbuminemia and related disorders. Kedbumin is a clear, slightly viscous solution that may have an amber, yellow, or green tint. It is stabilized with 0.08 mmol of sodium caprylate and 0.08 mmol of sodium acetyltryptophan per gram of albumin.
The primary indications for kedbumin include the treatment of hypoalbuminemia, fluid resuscitation, management of liver diseases, treatment of burns and trauma, and other conditions. Hypoalbuminemia is a condition characterized by low levels of albumin in the blood, which can lead to various health complications. Kedbumin is available in injectable formulations and lyophilized powders for reconstitution. Its target patient demographics encompass pediatric, adult, and geriatric patients. Distribution channels include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. Key end-users are hospitals, specialty clinics, home healthcare providers, pharmaceutical and biotechnology companies, and research institutions.
The kedbumin market research report is one of a series of new reports that provides kedbumin market statistics, including kedbumin industry global market size, regional shares, competitors with a kedbumin market share, detailed kedbumin market segments, market trends and opportunities, and any further data you may need to thrive in the kedbumin industry. This kedbumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The kedbumin market consists of sales of kedbumin products for medical and therapeutic use. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Kedbumin Market Characteristics4. Kedbumin Market Trends and Strategies5. Kedbumin Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Kedbumin Pricing Analysis & Forecasts30. Global Kedbumin Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Kedbumin Market32. Recent Developments in the Kedbumin Market
3. Kedbumin Market Biologic Drug Characteristics
6. Global Kedbumin Growth Analysis and Strategic Analysis Framework
8. Kedbumin Market Segmentation
9. Global Kedbumin Epidemiology of Clinical Indications
10. Kedbumin Market Regional and Country Analysis
11. Asia-Pacific Kedbumin Market
12. China Kedbumin Market
13. India Kedbumin Market
14. Japan Kedbumin Market
15. Australia Kedbumin Market
16. South Korea Kedbumin Market
17. Western Europe Kedbumin Market
18. UK Kedbumin Market
19. Germany Kedbumin Market
20. France Kedbumin Market
21. Eastern Europe Kedbumin Market
22. North America Kedbumin Market
23. USA Kedbumin Market
24. Canada Kedbumin Market
25. South America Kedbumin Market
26. Middle East Kedbumin Market
27. Africa Kedbumin Market
28. Kedbumin Market Competitive Landscape and Company Profiles
29. Global Kedbumin Market Pipeline Analysis
33. Kedbumin Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Kedbumin Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on kedbumin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for kedbumin? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kedbumin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Treatment of Hypoalbuminemia; Fluid Resuscitation; Management of Liver Diseases; Treatment of Burns and Trauma; Other Therapeutic Applications2) by Formulation: Injectable Formulation; Lyophilized Powder For Reconstitution
3) by Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients
4) by Distribution Channel: Direct Sales; Wholesalers and Distributors; Retail Pharmacies; Online Pharmacies
5) by End User: Hospitals; Specialty Clinics; Home Healthcare Providers; Pharmaceutical and Biotechnology Companies; Research Institutions
Key Companies Mentioned: Kedrion SpA
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Kedrion SpA
